alexa A Serological Study in Response to People at Occupational Risk of Rabies Virus Exposure in Nepal | Open Access Journals
ISSN: 2157-7560
Journal of Vaccines & Vaccination
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Serological Study in Response to People at Occupational Risk of Rabies Virus Exposure in Nepal

Ganesh Raj Pant1*, Arjun Raj Pant2, Bol Raj Acharya1, Manish Man Shrestha1, Vivek Pant3, Nayana Pant3 and Dwij Raj Bhatta4

1Rabies Vaccine Production Laboratory, Tripureshwor, Nepal

2Sukraraj Tropical Hospital, Teku, Nepal

3Institute of Medicine, TU, Maharajgunj, Nepal

4Central Department of Microbiology, TU, Kirtipur, Nepal

*Corresponding Author:
Ganesh Raj Pant
1Rabies Vaccine Production Laboratory
Tripureshwor, AFU, Chitawn, Nepal
Tel: 01-4109753
E-mail: pantganesh@hotmail.com

Received date: March 01, 2016 Accepted date: March 15, 2016 Published date: March 18, 2016

Citation: Pant GR, Pant AR, Acharya BR, Shrestha MM, Pant V, et al. (2016) A Serological Study in Response to People at Occupational Risk of Rabies Virus Exposure in Nepal. J Vaccines Vaccin 7:312. doi: 10.4172/2157-7560.1000312

Copyright: © 2016 Pant GR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Vaccines & Vaccination

Abstract

A serological study to know the antibody titer against rabies virus in human beings, who are at occupational risk, was conducted in Nepal in 2014. A total 44 serum samples were collected out of which 21 samples were collected from medical professionals (working at Sukraraj Tropical Hospital) and 23 were collected from veterinary professionals (working at Central Veterinary Hospital, Central Veterinary Laboratory and Rabies Vaccine Production Laboratory) in Kathmandu. Among the 44 samples, 4 were collected from unvaccinated persons. The other 40 people sampled were vaccinated with inactivated rabies vaccine. All samples were subjected to the Rabies Fluorescent Focus Inhibition Test (RFFIT) test at Centre for Disease Control and Prevention, Atlanta, USA. The antibody level of 7 persons was found to be less than the WHO recommended titer of 0.5 IU/ml. Six medical professionals and one veterinary professional had a low rabies virus neutralizing antibody titer. The 4 samples collected from unvaccinated persons, and 3 collected from vaccinated persons had a titer below 0.5 IU/ml. This study shows that medical and veterinary professionals who are responsible to nurse or handle rabies patients, rabid animals or rabies virus are still at high risk. This underscores the importance of recommendations for regular serological testing of occupationally exposed individuals and vaccinating booster dose when necessary.

Introduction

Rabies is endemic and priority zoonotic disease in Nepal. The death of 200 [1], human being and 300 animals [2], per year has been reported in this country. The disease has been confirmed in cattle, buffaloes, goats, alpaca, dogs and mongoose [3]. Rabies occurs throughout the year and dog is the principle vector for the transmission of disease. Rabies Vaccine Laboratory in Kathmandu produces 50, 000 doses of cell culture vaccine for animal use whereas vaccine for human use is imported from other countries [3]. Health authority purchased 300,000 doses expending 1 million USD every year to purchase inactivated cell culture rabies vaccine for human use (personal contact with EDCD). In 2012, 334,737 doses of cell culture rabies vaccine were purchased by Epidemiology and Disease Control Division, the Department of Health Service. Vaccine is not available to all victims at risk in country side therefore the case fatality is higher [4]. More than 45,000 people receive post exposure vaccination annually in Nepal. Number of dog bitten cases per month coming to Sukraraj Tropical Hospital (STH) for post exposure treatment is 1520 and in average 50 cases receives post exposure rabies vaccine daily in this hospital (Personal contact with STH Hospital).

Human or animal health workers, in contact with rabid animal or patient or rabies virus are at high risk of rabies infection. Therefore pre exposure rabies vaccine has been recommended by World Health Organization (WHO) for medical peoples, veterinarian and laboratory personals. The immunization protocol includes three injections, e.g. at days 0, 7, and 28. The serological evaluation of immunization is made 1-3 weeks after the last injection, and checked every 6 months in the case of laboratory workers or every 2 years for other diagnosticians. Booster vaccination must be given when the titer falls below 0.5 International Units (IU) per ml. In the absence of serological monitoring, the vaccination regimen should consist of a booster vaccination at 1 year and thereafter every 1-3 years [5,6]. Therefore the antibodies tire in response of rabies vaccine in vaccinated people or animal should be tested periodically by performing Rabies Fluorescent Focus Inhibition Test (RFFIT) after vaccination to avoid unnecessary vaccination and to reduce the risk of rabies infection. In this study we have measured antibody tire against rabies vaccine in professional people who have high risk hazard of Rabies.

Methodology

Blood samples were collected from 44 persons (13 female and 31 male) after getting oral consent in 2014. Sampled persons were 21 medical professional and 23 veterinary professional having occupational risk of rabies. Among medical professional 4 were doctors and 17 were technicians (paramedical) working at Sukraraj Tropical Hospital, Kathmandu. Among veterinary professional 9 working at Central Veterinary Hospital, 7 working at Central Veterinary Laboratory and 7 working at Rabies Vaccine Production Laboratory in Kathmandu. All 44 samples person were 28-58 years old. Among 44 collected samples, 4 were from unvaccinated persons and rest was from vaccinated persons in different time. Serum was separated labeled accordingly and stored at -20°C in refrigerator. The description of samples was presented in table 1. Samples were packed and transferred to Centre of Disease and Prevention Rabies Laboratory, Atlanta USA according to IATA instruction. The serum samples were subjected to RFFIT according to protocol described by World Health Organization (1996).

Sample No. Sex Titer IU/ml Recommendations
1 Male < 5 < 0.043 Recommendation boost
2 Female 6000 52 Adequate
3 Male 2200 19 Adequate
4 Female 45 0.39 Consider boost
5 Male 1200 10 Adequate
6 Male 1100 9.6 Adequate
7 Female > 390625 >3396 Adequate
8 Female 21 0.18 Recommended boost
9 Female < 5 < 0.043 Recommended boost
10 Male 15625 >136 Adequate
11 Female < 5 < 0.043 Recommended boost
12 Male 1900 16 Adequate
13 Male 145 1.3 Adequate
14 Male 230 2 Adequate
15 Male 1100 9.6 Adequate
16 Female 1100 9.6 Adequate
17 Male 5100 44 Adequate
18 Female < 5 < 0.043 Recommended boost
19 Male 1500 13 Adequate
20 Male 1300 11 Adequate
21 Female 280 2.4 Adequate
22 Male 1300 11 Adequate
23 Male 3125 50 Adequate
24 Male 250 8.6 Adequate
25 Female 270 4.3 Adequate
26 Male 3600 58 Adequate
27 Male 1300 21 Adequate
28 Female 70 1.1 Adequate
29 Male 7 0.11 Recommended boost
30 Male 1800 29 Adequate
31 Male 4200 67 Adequate
32 Male 4600 74 Adequate
33 Male 4200 67 Adequate
34 Female 270 4.3 Adequate
35 Male 2700 43 Adequate
36 Male 1900 30 Adequate
37 Male 110 1.8 Adequate
38 Male 1100 18 Adequate
39 Female 450 8.6 Adequate
40 Male 12000 192 Adequate
41 Male 1300 21 Adequate
42 Male 5100 82 Adequate
43 Male 210 3.4 Adequate
44 Male 1900 30 Adequate

Table 1: Result of RFFIT of human serum samples collected from Nepal in 2014.

Results and Discussion

The test revealed that 15.9% of tested samples had antibody titer 0.043 IU/ml below than WHO recommendation 0.5 IU/ml serum and 84.1% of tested samples had adequate titer ranging from 1.1 to 3316 IU/ml. Out of 40 sample collected from vaccinated person 7.5% had low antibody titer. The result of RFFIT has been presented in table 1. The variation of antibody titer was directly related to the number or frequency of dose, type of vaccine and duration between vaccination time and time of sample collection. Six medical professional and one veterinary professional had low level of titer. The low level of titer in 4 unvaccinated medical professional was normal and expected in control samples. Sample No. 1 revealed low titer because sampled person had taken nerve tissue post exposure vaccine 15 years ago. Low antibody titer of sample No. 8 (medical professional) and sample No. 29 (veterinary professional) might be due to lack of booster dose both of them had taken pre-exposure vaccination 1-3 years ago. However other factor such as host ability to immune response, quality of vaccine and health status may influence the production of antibody titer in host [7]. Sample No. 7 had highest titer 3396 IU/ml because

Sampled person had taken pre exposure cell culture inactivated vaccine and again booster dose 3 month ago. All 40 vaccinated people had taken inactivated cell culture vaccine except sample No. 1 and all sampled person with adequate antibody titer had taken booster in addition to pre or post exposure vaccine. This study showed that 15.9% of sampled professional were working at risk at Sukraraj Tropical Hospital and Central Veterinary Hospital were rabid patient were examined and treated. Among 7, 5 were female and 2 were male by sex. Therefore pre exposure vaccination and periodic sero-monitoring of antibody titer and administration of booster for person working at risk is urgent which is lacking in Nepal. WHO and World Organization for Animal Health has also recommended such preventive measures to be adopted by people at risk of rabies who work in medical and veterinary hospital or laboratories [4,8].

Conclusion

All medical or veterinary professional who are at risk of rabies infection are recommended to take pre-exposure inactivated cell culture rabies vaccine. Antibody titer in vaccinated persons should be tested periodically to ensure the antibody level of protection and to inject booster dose of vaccine accordingly.

Acknowledgements

Authors would like to acknowledge Dr. Todd Smith and Dr. Ashutosh Wadhwa, CDC, Atlanta, USA for their technical support and help conducting RFFIT test of Nepalese human serum samples at their laboratory and providing us result. Authors would like to thank CDC, Rabies Laboratory, Atlanta USA. The help of Sukraraj Tropical Hospital, Central Veterinary Laboratory, Central Veterinary Hospital and Rabies Vaccine Production Laboratory in Kathmandu for providing serum samples is highly appreciated.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 8239
  • [From(publication date):
    April-2016 - Oct 24, 2017]
  • Breakdown by view type
  • HTML page views : 8158
  • PDF downloads :81

Review summary

  1. Vsevolod
    Posted on Jul 13 2016 at 5:58 pm
    In this manuscript, Gamesj Raj Pant et al. report a serological study to study the antibody titer against rabies virus in human beings in Nepal in 2014 as a method to investigate the occurrence of the disease in medical and veterinary professionals. These individuals are at high risk of catching rabies since they are responsible to nurse and treat rabies patients and rabid animals. The results highlight the importance of recommendations for regular serological testing of occupationally exposed individuals and vaccinating booster dose when necessary. The results data are reasonably explained and well interpreted.
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords